Genprex Gestione

Gestione criteri di controllo 2/4

Genprex Il CEO è John Varner, nominato in Aug2012, e ha un mandato di 11.67 anni. la retribuzione annua totale è $ 2.53M, composta da 22% di stipendio e 78% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1% delle azioni della società, per un valore di € 40.71K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.1 anni e 4.1 anni.

Informazioni chiave

John Varner

Amministratore delegato

US$2.5m

Compenso totale

Percentuale dello stipendio del CEO	22.0%
Mandato del CEO	11.7yrs
Proprietà del CEO	1.0%
Durata media del management	3.1yrs
Durata media del Consiglio di amministrazione	4.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di John Varner rispetto agli utili di Genprex?
Data	Compenso totale	Stipendio	Guadagni aziendali
Dec 31 2023	n/a	n/a	-US$31m
Sep 30 2023	n/a	n/a	-US$31m
Jun 30 2023	n/a	n/a	-US$30m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$3m	US$557k	-US$24m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$21m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$2m	US$480k	-US$21m
Sep 30 2021	n/a	n/a	-US$19m
Jun 30 2021	n/a	n/a	-US$18m
Mar 31 2021	n/a	n/a	-US$19m
Dec 31 2020	US$2m	US$488k	-US$18m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$659k	US$400k	-US$11m
Sep 30 2019	n/a	n/a	-US$12m
Jun 30 2019	n/a	n/a	-US$11m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$1m	US$338k	-US$12m
Sep 30 2018	n/a	n/a	-US$10m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$3m
Dec 31 2017	US$334k	US$300k	-US$3m

Compensazione vs Mercato: La retribuzione totale di John ($USD 2.53M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 474.54K ).

Compensazione vs guadagni: La retribuzione di John è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

John Varner (66 yo)

11.7yrs

Mandato

US$2,532,399

Compensazione

Mr. John Rodney Varner is a co-founder of Genprex, Inc. He has been the Chief Executive Officer and Chairman of Genprex, Inc. since August 2012 and has been its President since August 10, 2020. He served a...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
John Varner	Co-Founder	11.7yrs	US$2.53m	1.0% € 40.7k
Ryan Confer	Chief Financial Officer	7.6yrs	US$1.14m	0.35% € 14.3k
David Schloss	Senior Vice President of Human Resources	2.3yrs	Nessun dato	Nessun dato
Thomas Gallagher	Senior Vice President of Intellectual Property & Licensing	3.6yrs	Nessun dato	Nessun dato
Mark Berger	Chief Medical Officer	2.6yrs	Nessun dato	0.25% € 10.3k
Suzanne Thornton-Jones	Senior Vice President of Regulatory Affairs & Quality	less than a year	Nessun dato	Nessun dato
Jack Roth	Chairman of Scientific & Medical Advisory Board	no data	Nessun dato	Nessun dato

3.1yrs

Durata media

66yo

Età media

Gestione esperta: Il team dirigenziale di 2DE0 è considerato esperto (durata media dell'incarico 3.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
John Varner	Co-Founder	11.7yrs	US$2.53m	1.0% € 40.7k
Jack Roth	Chairman of Scientific & Medical Advisory Board	no data	Nessun dato	Nessun dato
Brent Longnecker	Independent Director	4.1yrs	US$150.00k	0.046% € 1.9k
James E. Rothman	Strategic Advisor to the Board of Directors	11.8yrs	Nessun dato	Nessun dato
Pasi Antero Janne	Member of Scientific & Medical Advisory Board	no data	Nessun dato	Nessun dato
George Peoples	Member of Clinical Advisory Board	3.2yrs	Nessun dato	Nessun dato
Shu Kam Mok	Member of Scientific & Medical Advisory Board	no data	Nessun dato	Nessun dato
George Simon	Member of Scientific & Medical Advisory Board	no data	Nessun dato	Nessun dato
William Wilson	Independent Director	4.1yrs	US$140.00k	0% € 0
Jose Antonio Toscano	Independent Director	4.1yrs	US$150.00k	0% € 0
George Gittes	Member of Scientific Advisory Board	3.4yrs	Nessun dato	Nessun dato
Michael Morse	Member of Clinical Advisory Board	3.2yrs	Nessun dato	Nessun dato

4.1yrs

Durata media

66.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 2DE0 sono considerati esperti (durata media dell'incarico 4.1 anni).

Genprex Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Genprex, Inc Announces Executive Changes

Genprex, Inc., Annual General Meeting, Jun 18, 2024

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

High number of new directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Genprex, Inc. Receives Notice from Nasdaq Regarding Non-Compliance with Stockholders' Equity Requirement

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer

Genprex Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Genprex, Inc. Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc Announces Executive Changes

Genprex, Inc., Annual General Meeting, Jun 18, 2024

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc. has completed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

New major risk - Market cap size

No longer forecast to breakeven

Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics

Genprex Receives Non-Compliance Notice From Nasdaq

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

Genprex, Inc. announced delayed 10-Q filing

Genprex, Inc. Receives Fast Track Designation from the FDA for Its Small Cell Lung Cancer Drug Candidate

Genprex, Inc. Grants Chinese Patent for REQORSA(R) Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers

Genprex Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for the Treatment of Small Cell Lung Cancer

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Genprex, Inc. Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating Reqorsa Immunogene Therapy in Non-Small Cell Lung Cancer

Genprex, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

High number of new directors

High number of new and inexperienced directors

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

High number of new and inexperienced directors

High number of new and inexperienced directors

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

High number of new and inexperienced directors

Genprex, Inc. Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancercer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Announces Positive Preclinical Data for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System for Delivery of FAS DNA Plasmid to Treat Metastatic Colorectal Cancer

Genprex, Inc. to Accelerate Opening of Acclaim-1 Clinical Trial Sites

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc.(NasdaqCM:GNPX) dropped from Russell 3000E Index

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

Forecast to breakeven in 2024

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc. Announces Formation of Clinical Advisory Board

Genprex, Inc. Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer

Genprex, Inc Completes Manufacturing Technology Transfer for Novel Gene Therapy

Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc. Appoints George K. Gittes to Its Scientific Advisory Board

Genprex, Inc. Promotes Eric Chapdelaine to Vice President of Manufacturing

Genprex, Inc. Names Thomas C. Gallagher, Esq. as Senior Vice President of Intellectual Property and Licensing

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media